Illumina, Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Illumina, Inc. trades at $189.82 (market cap $27.94B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.72. The key difference: Illumina, Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | QDTE | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $194.33 | $36.60 |
52-Week Low | $91.00 | $26.85 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.22, up 0.31% on the day, while technical indicators signal a bearish trend with strong sell signals from moving averages. The ETF generates weekly dividends, with recent payouts ranging from $0.12 to $0.28, but financial ratios like P/E and P/S are unavailable. News highlights focus on its high distribution yield amid declining volatility, with comparisons to peers like XDTE.
Outlook remains cautious due to bearish technicals and fee concerns, though the weekly income strategy appeals to yield-seeking investors. Risks include sensitivity to market volatility and competitive pressure from other income ETFs. Investors should weigh the high yield against potential capital erosion from covered call strategies.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →